Subtype distribution of hepatitis C virus in Jiangsu, China.
Hepatitis C virus (HCV) genotype distribution varied by regions and transmission modes. In this study, we investigated HCV genotype distribution in five cities of Jiangsu, China, all of which are located in the Yangtze River Delta Region. A total of 363 samples were collected during 2011-2012. C/E2 and NS5B fragments of HCV were amplified using a multiple RT-nested PCR strategy and subjected to sequencing. Phylogenetic analysis was performed for HCV genotyping. Among 106 PCR positive cases, HCV subtypes 1a (0.9%), 1b (61.3%), 2a (15.1%), 3a (4.7%), 3b (9.4%), 6a (6.6%), and 6n (1.9%) were detected. Together with our previous data, we found that HCV subtypes were more among injection drug users (IDUs) (nine) than among general population (GP) (six), and the most common subtype among GP was 1b (73.9%), followed by 2a (14.5%), while the top four common subtypes among IDUs were 3a, 1b, 3b, and 6a, with similar prevalence rates (24.4%, 22.7%, 20.9%, and 17.4%, respectively). There were nine HCV subtypes prevalent among IDUs in Jiangsu, more than those in Xinjiang, Hubei, Yunnan, Guangxi, Guangdong, and Hong Kong. The top four common subtypes among IDUs in Jiangsu covered all the two most common HCV subtypes (except 6n subtype) observed in six targeted provinces/region. These results suggested that Jiangsu may be an important gathering place for various HCV subtypes and the gathering may be involved in the large scale of population migration from other regions of China to Eastern China.
Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, China.
Yinle
Y
Qi
Pathogen Diagnostic Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Qianqian
Q
Chen
Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, China.
Fangyuan
F
Hao
Medical Laboratory of Taizhou Fourth People's Hospital, Taizhou, Jiangsu, China.
Zhenzhou
Z
Wan
Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu, China.
Hongxiong
H
Guo
The Third People's Hospital of Nantong, Nantong, Jiangsu, China.
Renfei
R
Lu
Zhenjiang Center of Disease Control and Prevention, Zhenjiang, Jiangsu, China.
Lingxiang
L
Mao
Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Hong
H
Du
Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, China.
Jian
J
Lu
Institute of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, China.|Pathogen Diagnostic Center, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
Chiyu
C
Zhang
D002681:China / Q000453:epidemiology; D014644:Genetic Variation; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology / Q000635:transmission / Q000821:virology*; D063426:Human Migration; D006801:Humans; D010802:Phylogeny; D016133:Polymerase Chain Reaction; D015995:Prevalence; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D017422:Sequence Analysis, DNA; D015819:Substance Abuse, Intravenous / Q000150:complications / Q000821:virology; D014759:Viral Envelope Proteins / Q000235:genetics; D017361:Viral Nonstructural Proteins / Q000235:genetics
D012367:RNA, Viral; D014759:Viral Envelope Proteins; D017361:Viral Nonstructural Proteins
HCV; Jiangsu; general population; injection drug users; population migration; subtype